BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

Yuxiang Ma; Yan Huang; Yuanyuan Zhao; Shen Zhao; Jinhui Xue; Yunpeng Yang; Wen‐Feng Fang; Ye Guo; Yaqian Han; Kunyu Yang; Yongsheng Li; Jun Yang; Zhenming Fu; Gang Chen; Likun Chen; Ningning Zhou; Ting Zhou; Yaxiong Zhang; Huaqiang Zhou; Qianwen Liu; Yi Zhu; Hai Zhu; Sa Xiao; Li Zhang; Hongyun Zhao

doi:10.1016/s1470-2045(24)00159-1

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study | Litlas